Delivery Order SPE2DB20D9214-SPE2DB25FD4YF
- Not listed
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $37,659.45 to DMS Pharmaceutical Group Inc. for EXPAREL 266 mg/20 mL vials. The order was issued on September 11, 2025, with an ultimate completion date of October 2, 2025. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was selected without a set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's existing...
- The Defense Logistics Agency (DLA) awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EXPAREL 266 mg/20 ml vials. The contract is a firm fixed-price delivery order with a ceiling value of $12,553.15 and an ultimate completion date of August 4, 2025. This award was made without a set-aside designation, and the place of performance is Park Ridge, Illinois. DMS Pharmaceutical Group is...
- The Defense Logistics Agency awarded DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, a firm fixed-price delivery order valued at $15,063.78 for EXPAREL 266 mg/20 ml vials. The award, issued on June 18, 2025, with an ultimate completion date of July 11, 2025, carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA's SPE2DB program, a $500...
- The Defense Logistics Agency (DLA) awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EXPAREL 266 mg/20 mL vials. The contract, valued at $2,510.63 with a firm fixed-price structure, was executed on August 13, 2025, with an ultimate completion date of September 4, 2025. EXPAREL is a liposomal bupivacaine formulation used for extended local anesthesia, and this delivery order falls...
- The Defense Logistics Agency awarded a delivery order valued at $15,063.78 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EXPAREL 266 mg/20 mL vials. This firm fixed-price delivery order was awarded on August 12, 2025, with an ultimate completion date of September 3, 2025, and carries no set-aside designation. The award falls under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the...
- The Defense Logistics Agency awarded a firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EXPAREL (liposomal bupivacaine) 266 mg/20 mL vials. The contract, valued at approximately $25.1K, carries an ultimate completion date of September 29, 2025, and was issued on September 8, 2025. This delivery order does not utilize a set-aside designation, allowing DMS Pharmaceutical Group...
- The Defense Logistics Agency awarded a delivery order valued at $8,234.32 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EXPAREL 266 mg/20 ml vials. This firm fixed-price delivery order, issued on August 28, 2025, with an ultimate completion date of September 19, 2025, was executed without a set-aside designation. The order is issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $125,531.50 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EXPAREL (liposomal bupivacaine) 266 mg/20 mL vials. This firm fixed-price delivery order, issued on July 11, 2025, with an ultimate completion date of August 1, 2025, represents a direct procurement with no set-aside designation. The award falls under DMS Pharmaceutical Group's...
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $17,574.41 to DMS Pharmaceutical Group Inc. on August 11, 2025, for the supply of EXPAREL 266 mg/20 mL vials. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform this contract at its Park Ridge facility with an ultimate completion date of September 2, 2025. This delivery order was issued without a set-aside designation, allowing...
- The Defense Logistics Agency awarded a $25,106.30 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. on July 31, 2025, for the supply of EXPAREL 266 mg/20 mL vials. This delivery order, which carries an ultimate completion date of August 21, 2025, represents a task order issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA valued at $500 million through November 2026. The award was made without set-aside designation, allowing DMS Pharmaceutical Group...
- SPE2DB20D9214Indefinite Delivery Contract
- SPE2DB20D9214-SPE2DB25FD4YFDelivery Order
The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EXPAREL 266 mg/20 ml vials. This firm fixed-price delivery order, valued at $15,063.78 with an ultimate completion date of October 9, 2025, was issued without a set-aside designation. The award leverages DMS Pharmaceutical Group's position as a critical supplier within the federal pharmaceutical supply chain, supported by its substantial single-award Indefinite Delivery Contract with the DLA valued at $499,999,999 through November 2026. EXPAREL is a liposomal bupivacaine product used for long-acting local anesthesia and pain management in surgical and medical settings. This delivery order represents a routine pharmaceutical procurement under the DLA's broader pharmaceutical supply program, which ensures military health facilities and Department of Defense healthcare sites maintain access to essential medications and medical consumables. DMS Pharmaceutical Group's continued engagement in such procurements reflects its established role in supporting military healthcare operations through reliable distribution of branded pharmaceutical products and specialty medications across the federal supply system.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $15.1k | 9/18/25 |